Fluorescein hydrazones as novel nonintercalative topoisomerase catalytic inhibitors with low DNA toxicity

J Med Chem. 2014 Nov 13;57(21):9139-51. doi: 10.1021/jm501263m. Epub 2014 Nov 5.

Abstract

Fluorescein hydrazones (3a-3l) were synthesized in three steps with 86-91% overall yields. Topo I- and IIα-mediated relaxation and cell viability assay were evaluated. 3d inhibited 47% Topo I (camptothecin, 34%) and 20% Topo II (etoposide 24%) at 20 μM. 3l inhibited 61% Topo II (etoposide 24%) at 20 μM. 3d and 3l were further evaluated to determine their mode of action with diverse methods of kDNA decatenation, DNA-Topo cleavage complex, comet, DNA intercalating/unwinding, and Topo IIα-mediated ATP hydrolysis assays. 3d functioned as a nonintercalative dual inhibitor against the catalytic activities of Topo I and Topo IIα. 3l acted as a Topo IIα specific nonintercalative catalytic inhibitor. 3d activated apoptotic proteins as it increased the level of cleaved capase-3 and cleaved PARP in a dose- and time-dependent manner. The dose- and time-dependent increase of G1 phase population was observed by treatment of 3d along with the increase of p27(kip1) and the decrease of cyclin D1 expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm
  • Apoptosis / drug effects
  • Cell Proliferation / drug effects
  • DNA Topoisomerases, Type I
  • DNA Topoisomerases, Type II
  • DNA-Binding Proteins
  • Fluorescein / chemistry
  • HEK293 Cells
  • Humans
  • Hydrazones / chemical synthesis*
  • Topoisomerase Inhibitors / chemical synthesis*

Substances

  • Antigens, Neoplasm
  • DNA-Binding Proteins
  • Hydrazones
  • Topoisomerase Inhibitors
  • DNA Topoisomerases, Type I
  • TOP1 protein, human
  • DNA Topoisomerases, Type II
  • Fluorescein